Emmani B. M. Nascimento

Emmani B. M. Nascimento

Auto-generated profile, based on publicly available information

Emmani B. M. Nascimento

Maastricht University

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2015 in Cell Metabolism
Verified
Journal Article
Closed access
EBEvie P.M. Broeders
Evie P.M. Broeders
ENEmmani B.M. Nascimento
Emmani B.M. Nascimento
BHBas Havekes
Bas Havekes
BBBoudewijn Brans
Boudewijn Brans
KRKay H.M. Roumans
Kay H.M. Roumans
PSPatrick Schrauwen
Patrick Schrauwen

20 July 2015 in International Journal of Obesity
Verified
Journal Article
Closed access
PDF file
MVM J Vosselman
M J Vosselman
JHJ Hoeks
J Hoeks
BBB Brans
B Brans
HPH Pallubinsky
H Pallubinsky
ENE B M Nascimento
E B M Nascimento
WLW D van Marken Lichtenbelt
W D van Marken Lichtenbelt

15 June 2012 in American Journal of Physiology-Endocrinology and Metabolism
Verified
Journal Article
Closed access
PDF file
CWClaudia Wiza
Claudia Wiza
ENEmmani B. M. Nascimento
Emmani B. M. Nascimento
DOD. Margriet Ouwens
D. Margriet Ouwens
The proline-rich Akt substrate of 40 kDa (PRAS40) acts at the intersection of the Akt- and mammalian target of rapamycin (mTOR)-mediated signaling pathways. The protein kinase mTOR is the catalytic subunit of two distinct signaling complexes, mTOR complex 1 (mTORC1) and mTORC2, that link energy and nutrients to the regulation of cellular growth and energy metabolism. Activation of mTOR in response to nutrients and growth factors results in the phosphorylation of numerous substrates, including the phosphorylations of S6 kinase by mTORC1 and Akt by mTORC2. Alterations in Akt and mTOR activity have been linked to the progression of multiple diseases such as cancer and type 2 diabetes. Although PRAS40 was first reported as substrate for Akt, investigations toward mTOR-binding partners subsequently identified PRAS40 as both component and substrate of mTORC1. Phosphorylation of PRAS40 by Akt and by mTORC1 itself results in dissociation of PRAS40 from mTORC1 and may relieve an inhibitory constraint on mTORC1 activity. Adding to the complexity is that gene silencing studies indicate that PRAS40 is also necessary for the activity of the mTORC1 complex. This review summarizes the regulation and potential function(s) of PRAS40 in the complex Akt- and mTOR-signaling network in health and disease.

1 June 2010 in Cellular Signalling
Verified
Journal Article
Closed access
ENEmmani B.M. Nascimento
Emmani B.M. Nascimento
MSMarieke Snel
Marieke Snel
Bruno GuigasBruno Guigas
Bruno Guigas
GZGerard C.M. van der Zon
Gerard C.M. van der Zon
JKJan Kriek
Jan Kriek
DOD. Margriet Ouwens
D. Margriet Ouwens

1 June 2018 in Molecular Metabolism
Verified
Journal Article
Open access
MLMarlies de Ligt
Marlies de Ligt
YBYvonne M.H. Bruls
Yvonne M.H. Bruls
JHJan Hansen
Jan Hansen
MHMarie-Fleur Habets
Marie-Fleur Habets
BHBas Havekes
Bas Havekes
PSPatrick Schrauwen
Patrick Schrauwen
Resveratrol supplementation improves metabolic health in healthy obese men, but not in patients with type 2 diabetes (T2D) when given as add-on therapy. Therefore, we examined whether resveratrol can enhance metabolic health in men at risk of developing T2D. Additionally, we examined if resveratrol can stimulate brown adipose tissue (BAT). Thirteen male first degree relatives (FDR) of patients with T2D received resveratrol (150 mg/day) and placebo for 30 days in a randomized, placebo controlled, cross-over trial. Resveratrol significantly improved ex vivo muscle mitochondrial function on a fatty acid-derived substrate. However, resveratrol did not improve insulin sensitivity, expressed as the rate of glucose disposal during a two-step hyperinsulinemic-euglycemic clamp. Also, intrahepatic and intramyocellular lipid content, substrate utilization, energy metabolism, and cold-stimulated 18F-FDG glucose uptake in BAT (n = 8) remained unaffected by resveratrol. In vitro experiments in adipocytes derived from human BAT confirmed the lack of effect on BAT. Resveratrol stimulates muscle mitochondrial function in FDR males, which is in concordance with previous results. However, no other metabolic benefits of resveratrol were found in this group. This could be attributed to subject characteristics causing alterations in metabolism of resveratrol and thereby affecting resveratrol's effectiveness. CLINICALTRIALS. NCT02129595.

1 December 2006 in Diabetes
Verified
Journal Article
Open access
PDF file
ENEmmani B.M. Nascimento
Emmani B.M. Nascimento
MFMariann Fodor
Mariann Fodor
GZGerard C.M. van der Zon
Gerard C.M. van der Zon
IJIngrid M. Jazet
Ingrid M. Jazet
AMA. Edo Meinders
A. Edo Meinders
DOD. Margriet Ouwens
D. Margriet Ouwens
Clinical insulin resistance is associated with decreased activation of phosphatidylinositol 3′-kinase (PI3K) and its downstream substrate protein kinase B (PKB)/Akt. However, its physiological protein substrates remain poorly characterized. In the present study, the effect of in vivo insulin action on phosphorylation of the PKB/Akt substrate 40 (PRAS40) was examined. In rat and mice, insulin stimulated PRAS40-Thr246 phosphorylation in skeletal and cardiac muscle, the liver, and adipose tissue in vivo. Physiological hyperinsulinemia increased PRAS40-Thr246 phosphorylation in human skeletal muscle biopsies. In cultured cell lines, insulin-mediated PRAS40 phosphorylation was prevented by the PI3K inhibitors wortmannin and LY294002. Immunohistochemical and immunofluorescence studies showed that phosphorylated PRAS40 is predominantly localized to the nucleus. Finally, in rats fed a high-fat diet (HFD), phosphorylation of PRAS40 was markedly reduced compared with low-fat diet–fed animals in all tissues examined. In conclusion, the current study identifies PRAS40 as a physiological target of in vivo insulin action. Phosphorylation of PRAS40 is increased by insulin in human, rat, and mouse insulin target tissues. In rats, this response is reduced under conditions of HFD-induced insulin resistance.